{"id":"W3018886418","doi":"10.1016/s1474-4422(20)30078-8","title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":490,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"National Eye Institute; Genentech; Multiple Sclerosis Society of Canada; Japan Blood Products Organization; National Institutes of Health; Guthy-Jackson Charitable Foundation; Patient-Centered Outcomes Research Institute; Bayer Canada; Bayer; Biogen; Teva Pharmaceutical Industries; Otsuka Pharmaceutical; Novartis; National Multiple Sclerosis Society; MedImmune; Chugai Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Roche","keywords":"Medicine; Placebo; Clinical endpoint; Population; Neuromyelitis optica; Internal medicine; Clinical trial; Intention-to-treat analysis; Pediatrics; Antibody; Immunology; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003032073,0.002301387,0.004499247,0.0005086542,0.0008013391,0.001482315,0.001166063,0.003641465,0.006460566],"category_scores_gemma":[0.00287756,0.0009268916,0.003490378,0.0005182109,0.002108707,0.001637936,0.0004996107,0.003713073,0.001443273],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001031756,"about_ca_system_score_gemma":0.001418232,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001104988,"about_ca_topic_score_gemma":0.001517367,"domain_scores_codex":[0.9987923,0.0005956929,0.0001041766,0.0002536784,0.0001024799,0.0001515802],"domain_scores_gemma":[0.9984206,0.0005652161,0.0003622345,0.000149681,0.0001239235,0.0003784178],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9915473,0.001272973,0.0002880803,0.0004229994,0.0007434076,0.00002498119,0.00003925624,0.0001046674,0.001446476,0.0000485711,0.0003183331,0.003743143],"study_design_scores_gemma":[0.9729376,0.02538129,0.0008235472,0.00002087109,0.000285968,0.00001755742,0.00001189675,0.0001152226,0.0001332082,0.00007992784,0.0001830368,0.000009728265],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9832987,0.008044655,0.0007405644,0.0009021263,0.0009064814,0.002922315,0.001402731,0.0001203699,0.001662044],"genre_scores_gemma":[0.9870702,0.002531887,0.001531187,0.00127787,0.0006386507,0.003437387,0.001172124,0.00003111951,0.002309603],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006460566,"threshold_uncertainty_score":0.02161276,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06748685005283493,"score_gpt":0.3488388857934585,"score_spread":0.2813520357406236,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}